Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia | Synapse
March 3, 2026
Design and optimization of selective and potent LSD1 inhibitors with tranylcypromine-pyrimidine scaffold for the treatment of acute myeloid leukemia
Key Points
Inhibitors targeting LSD1 effectively reduced cancer cell proliferation in acute myeloid leukemia.
Key metrics include a potency improvement of over 50% when tested in vitro against leukemia cell lines.
Design and optimization focus on the tranylcypromine-pyrimidine scaffold for enhanced inhibition of LSD1.
Highlights the need for further research into targeted therapies for acute myeloid leukemia; validation required.